Presenters
Endocrinologist, Sunway Medical Centre
ALEXANDER TAN, MD
Course Details
Type 2 diabetes is one of the leading causes of mortality worldwide and is a major cause of stroke, heart disease, kidney failure, blindness and other conditions. The successful management of this disease is often complex, requiring multiple considerations beyond glycemic control. This course will discuss the most recent guidelines, management strategies, and clinical outcomes of patients with Type 2 Diabetes and how Empagliflozin can address the cardio-renal-metabolic systems.
CPD Points: 0.5 Point
PRC Program No: PROG-2021-20671
Breaking Down the Evidence: Empagliflozin’s Role in Improving Glucose Control and CV Outcomes in T2D Patients Course Outline
- To update on the latest available guidelines on the treatment of patients with type 2 diabetes ESC, ADA/EASD, KDIGO
- To provide updates on the mechanism of action of the latest available oral anti-diabetic drugs specifically on empagliflozin.
- To discuss on the connection of metabolic-cardio-renal mechanisms of oral anti-diabetic drugs and its impact to disease outcomes particularly in cardiovascular and renal disease.